Adipose tissue gene expression of CXCL10 and CXCL11 modulates inflammatory markers in obesity: implications for metabolic inflammation and insulin resistance.
CXCL10
CXCL11
CXCL9
adipose tissue
insulin resistance
metabolic inflammation
obesity
Journal
Therapeutic advances in endocrinology and metabolism
ISSN: 2042-0188
Titre abrégé: Ther Adv Endocrinol Metab
Pays: United States
ID NLM: 101532143
Informations de publication
Date de publication:
2020
2020
Historique:
received:
14
10
2019
accepted:
10
05
2020
entrez:
14
7
2020
pubmed:
14
7
2020
medline:
14
7
2020
Statut:
epublish
Résumé
The CXCL subfamily of chemokines (CXCL9, CXCL10, and CXCL11; angiostatic chemokines) plays a key role in many inflammatory diseases. However, the expression of CXCLs in adipose tissue (AT) during obesity and association of these CXCLs with inflammatory markers and insulin resistance are poorly understood. Therefore, this study aimed to investigate the effects of CXCL gene expression on subcutaneous AT inflammatory markers and insulin resistance. Subcutaneous-fat biopsies were collected from 59 nondiabetic (lean/overweight/obese) individuals for RNA isolation. Expression levels of AT CXCL and inflammatory markers were determined by quantitative reverse transcriptase polymerase chain reaction (RT-qPCR). Biomedical parameters in the plasma were measured by enzyme-linked AT CXCL expression was higher in obese compared with lean individuals ( These data suggest that the CXCL family members, specifically CXCL10 and CXCL11, are potential biomarkers for the onset of AT inflammation during obesity.
Sections du résumé
BACKGROUND
BACKGROUND
The CXCL subfamily of chemokines (CXCL9, CXCL10, and CXCL11; angiostatic chemokines) plays a key role in many inflammatory diseases. However, the expression of CXCLs in adipose tissue (AT) during obesity and association of these CXCLs with inflammatory markers and insulin resistance are poorly understood. Therefore, this study aimed to investigate the effects of CXCL gene expression on subcutaneous AT inflammatory markers and insulin resistance.
METHODS
METHODS
Subcutaneous-fat biopsies were collected from 59 nondiabetic (lean/overweight/obese) individuals for RNA isolation. Expression levels of AT CXCL and inflammatory markers were determined by quantitative reverse transcriptase polymerase chain reaction (RT-qPCR). Biomedical parameters in the plasma were measured by enzyme-linked
RESULTS
RESULTS
AT CXCL expression was higher in obese compared with lean individuals (
CONCLUSION
CONCLUSIONS
These data suggest that the CXCL family members, specifically CXCL10 and CXCL11, are potential biomarkers for the onset of AT inflammation during obesity.
Identifiants
pubmed: 32655851
doi: 10.1177/2042018820930902
pii: 10.1177_2042018820930902
pmc: PMC7331767
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2042018820930902Informations de copyright
© The Author(s), 2020.
Déclaration de conflit d'intérêts
Conflict of interest statement: The authors declare that there is no conflict of interest.
Références
Diabetol Metab Syndr. 2015 Aug 27;7:71
pubmed: 26312071
J Immunol. 2018 May 15;200(10):3599-3611
pubmed: 29632147
FEBS Lett. 2008 Jan 9;582(1):97-105
pubmed: 18053812
J Clin Endocrinol Metab. 2014 Jan;99(1):39-48
pubmed: 24187406
J Inflamm (Lond). 2012 Nov 28;9(1):48
pubmed: 23191980
J Immunol. 1998 Jul 15;161(2):927-32
pubmed: 9670971
Cancer Treat Rev. 2018 Feb;63:40-47
pubmed: 29207310
Science. 1993 Jan 1;259(5091):87-91
pubmed: 7678183
Am J Physiol Endocrinol Metab. 2015 Jan 1;308(1):E71-83
pubmed: 25370852
World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253
pubmed: 11234459
Biochim Biophys Acta. 2014 Nov;1843(11):2563-2582
pubmed: 24892271
Int J Mol Sci. 2019 Jan 17;20(2):
pubmed: 30658440
J Immunol Res. 2016;2016:4396368
pubmed: 27795961
Gastroenterol Clin North Am. 2016 Dec;45(4):571-579
pubmed: 27837773
Circ Res. 2016 May 27;118(11):1786-807
pubmed: 27230642
Int J Obes (Lond). 2018 Aug;42(8):1406-1417
pubmed: 29795466
Cells. 2019 Nov 11;8(11):
pubmed: 31718015
Mol Med. 2011;17(7-8):840-5
pubmed: 21394384
Obesity (Silver Spring). 2014 May;22(5):1264-74
pubmed: 24124129
J Inflamm (Lond). 2016 Dec 8;13:38
pubmed: 27980459
Annu Rev Pathol. 2007;2:31-56
pubmed: 18039092
Obes Rev. 2015 Apr;16(4):319-26
pubmed: 25752756
Hypertension. 2013 Jul;62(1):126-33
pubmed: 23716586
J Cardiovasc Transl Res. 2016 Aug;9(4):302-14
pubmed: 27271043
PLoS One. 2015 Jul 22;10(7):e0133494
pubmed: 26200663
Diabetes Metab Res Rev. 2019 Feb;35(2):e3087
pubmed: 30339734
Biomolecules. 2015 Jul 21;5(3):1563-79
pubmed: 26197341
Endocr Metab Immune Disord Drug Targets. 2007 Jun;7(2):111-23
pubmed: 17584151
Cell Physiol Biochem. 2018;45(2):572-590
pubmed: 29428931
J Clin Invest. 2006 Jul;116(7):1793-801
pubmed: 16823477
Thromb Haemost. 2013 Oct;110(4):661-8
pubmed: 23595655
Ann Transl Med. 2017 Apr;5(7):161
pubmed: 28480197
Obes Rev. 2008 Jan;9(1):20-9
pubmed: 17956545
Mol Cell Biol. 2015 Nov 16;36(3):376-93
pubmed: 26572826
FEBS J. 2018 Aug;285(16):2944-2971
pubmed: 29637711
PLoS One. 2013 May 13;8(5):e63944
pubmed: 23675517
J Clin Endocrinol Metab. 2008 Aug;93(8):3215-21
pubmed: 18492752
Diabetes. 2009 Mar;58(3):718-25
pubmed: 19074987
PLoS One. 2011;6(6):e21174
pubmed: 21731663
Arch Immunol Ther Exp (Warsz). 2013 Apr;61(2):119-25
pubmed: 23307037
Genes Dev. 2007 Jun 15;21(12):1443-55
pubmed: 17575046